Литература

Поставить закладку

1. Краснопольская КД. Наследственные болезни обмена веществ: Справочное пособие для врачей. — М.: Фохат, 2005.
2. Воробьев А. И., Бриллиант М. Д., Лукина Е. А. Болезнь Гоше // Руководство по гематологии. Под ред. АИ Воробьева. — М.: Ньюдиамед, 2003; т. 2, с. 202—205.
3. Лукина Е. А. Болезнь Гоше // Рациональная фармакотерапия заболеваний системы крови. Под ред. АИ Воробьева. — М.: Литерра, 2009; с. 563—566.
4. Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides: evidence of an enzymatic deficiency in Gaucher disease. Biochem Biophys Res Commun 1965; 18:221—225.
5. Mistry PK. Gaucher disease: a model for modern management of a genetic disease. J Hepatol 1999; 30:1—5.
6. Poll LW, Terk MR. Skeletal aspects of Gaucher disease. Brit J Radiol 2002; 75(Suppl 1):A1— A42.
7. Лукина К. А. Клинические и молекулярные факторы, ассоциированные с поражением костно-суставной системы при болезни Гоше I типа. Дисс. канд. мед. наук. — М., 2013.
8. Zimran A, Kay A, Beutler E et al. Gaucher disease: clinical, laboratory, radiologic and genetic features of 53 patients. Medicine 1992; 71:337—353.
9. Di Rocco M, Giona F, Carubbi F et al. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica 2008; 93:1211— 1218.
10. Gaucher Disease. Eds AH Futerman, A Zimran. — Boca Raton, FL: Taylor & Francis, 2007.
11. Lee RE. The pathology of Gaucher disease. Prog Clin Biol Res 1982; 95:177—217.
12. Weinreb NJ. Type I Gaucher disease in elderly patients. Gaucher Clinical Perspectives 1999; 7:1—8.
13. The Human Gene Mutation Database Professional, October 2017 (http://www.hgmd.cf.ac.uk/ac/index.php).
14. Grabowski GA. Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Test 1997; 1:5—12.
15. Cox TM. Gaucher's disease — an exemplary monogenic disorder. QJM 2001; 94:399—402.
16. Pastores GM, Weinreb NJ, Aerts H et al. Therapeutic goals in the treatment of Gaucher disease. Semin. Hematol. 2004 Oct; 41 (4 Suppl 5): 4—14
17. Biegstraaten M, Cox TM, Belmatoug N et al. Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis 2018; 68:203—208.
18. Zimran A. How I treat Gaucher disease. Blood 2011; 118:1463—1471.
19. Zimran A, Elstein D, Gonzalez Derlis E et al. Treatment-naive Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4 years in phase 3 trials. Blood Cells Mol Dis 2018; 68:153—159.
20. Ficicioglu C. Review of miglustat for clinical management in Gaucher disease type 1. Ther Clin Risk Manag 2008; 4:425—431.
21. Lukina E, Watman N, Arreguin EA et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 2010; 116:893—899.
22. Lukina E, Watman N, Arreguin EA et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 2010; 116:4095—4098.
23. Cox TM, Drelichman G, Cravo R et al. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. Blood 2017; 129:2375—2383.
24. Mistry PK, Lukina E, Ben Turkia H et al. Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: The phase 3 ENGAGE trial. Am J Hematol 2017; 92:1170---1176.
25. Lau H, Belmatoug N, Deegan P et al. Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey. Blood Cells Mol Dis 2016; 68:226—231.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница